-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference
PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference
FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that its management will present at the H.C. Wainwright 24th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.
H.C. Wainwright Global Investment Conference
Date: Monday, September 12, 2022
Time: On-demand presentation at 7:00 AM EDT
Investors can register for the webcast here
Following the conference, a webcast replay of the presentation will be available on the Investor section of the company's website, PDS Biotechnology.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit or follow us on Twitter at @PDSBiotech.
Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital
FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that its management will present at the H.C. Wainwright 24th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.
新泽西州弗洛拉姆公园，9月2022年06日(环球通讯社)--PDS生物技术公司(纳斯达克：PDSB)，一家临床阶段的免疫治疗公司，基于该公司的专利Versamune，开发越来越多的靶向癌症免疫治疗和传染病疫苗流水线®和Infectimune™T细胞激活技术公司今天宣布，其管理层将出席2022年9月12-14日在纽约市乐天纽约皇宫酒店举行的H.C.温赖特第24届全球投资年会。
H.C. Wainwright Global Investment Conference
Date: Monday, September 12, 2022
Time: On-demand presentation at 7:00 AM EDT
Investors can register for the webcast here
H.C.温赖特全球投资大会
日期：2022年9月12日(星期一)
时间：美国东部时间上午7：00点播演示
投资者可以在此处注册观看网络直播
Following the conference, a webcast replay of the presentation will be available on the Investor section of the company's website, PDS Biotechnology.
会议结束后，演示文稿的网络直播将在该公司网站PDS Biotech的投资者栏目上播出。
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit or follow us on Twitter at @PDSBiotech.
关于PDS生物技术
PDS Biotech是一家临床阶段的免疫治疗公司，基于我们的专利Versamune，正在开发不断增长的靶向癌症和传染病免疫治疗流水线®和传染病™T细胞激活技术平台。我们相信我们的目标Versamune®通过诱导大量高质量、高功能的肿瘤特异性CD4+辅助细胞和CD8+杀伤T细胞，候选候选细胞有可能克服目前免疫治疗的局限性。到目前为止，我们的主演Versamune®临床候选药物PDS0101已经在多个第二阶段临床试验中证明了与批准的和研究中的疗法相结合，能够减少肿瘤和稳定疾病的能力，治疗范围广泛的HPV16相关癌症。到目前为止的临床前研究表明，我们的基于感染™的疫苗不仅可以诱导强大而持久的中和抗体反应，还可以诱导强大的T细胞反应，包括持久的记忆性T细胞反应。要了解更多信息，请访问或在Twitter上关注我们@PDSBiotech。
Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
投资者联系方式：
黛安·兰道夫
PDS生物技术公司
电话：+1(908)517-3613
电子邮件：drandolph@pdsBiotech.com
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital
里奇·科克雷尔
CG资本
电话：+1(404)736-3838
电子邮件：pdsb@cg.Capital
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧